Browsing by Author "Jabbour, E."
Now showing items 1-1 of 1
-
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
Cortes, J. E.; Hochhaus, A.; le Coutre, P. D.; Rosti, G.; Pinilla-Ibarz, J.; Jabbour, E.; Gillis, K.; Woodman, R. C.; Blakesley, R. E.; Giles, F. J.; Kantarjian, H. M.; Baccarani, M. (American Society of Hematology, 2011-04-05)Nilotinib has significant efficacy in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and in patients with CML-CP or CML in accelerated phase (CML-AP) after imatinib failure. We investigated ...